Shingo Matsumoto

Shingo Matsumoto

Auto-generated profile, based on publicly available information

Shingo Matsumoto

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAkira Sugimoto
Akira Sugimoto
SMShingo Matsumoto
Shingo Matsumoto
HUHibiki Udagawa
Hibiki Udagawa
RIRyo Itotani
Ryo Itotani
YUYuko Usui
Yuko Usui
KGKoichi Goto
Koichi Goto
Purpose: We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid). Experimental Design: Blood samples were prospectively collected within 4 weeks of corresponding tumor tissue sampling from patients with advanced NSCLC to investigate plasma cfDNA sequencing concordance for alterations in 8 oncogenes (EGFR, KRAS, BRAF, HER2, MET, ALK, RET, and ROS1) compared with tissue-based next-generation targeted sequencing. Results: Paired blood and tissue samples were obtained in 1,062/1,112 enrolled patients with NSCLC. Oncogenic alteration was detected by plasma cfDNA sequencing and tissue assay in 455 (42.8%) and 537 (50.5%) patients, respectively. The positive percent agreement of plasma cfDNA sequencing compared with tissue DNA and RNA assays were 77% (EGFR, 78%; KRAS, 75%; BRAF, 85%; HER2, 72%) and 47% (ALK, 46%; RET, 57%; ROS1, 18%; MET, 66%), respectively. Oncogenic drivers were positive for plasma cfDNA and negative for tissue due to unsuccessful genomic analysis from poor-quality tissue samples (70%), and were negative for plasma cfDNA and positive for tissue due to low sensitivity of cfDNA analysis (61%). In patients with positive oncogenic drivers by plasma cfDNA sequencing but negative by tissue assay, the response rate of genotype-matched therapy was 85% and median progression-free survival was 12.7 months. Conclusions: Plasma cfDNA sequencing in patients with advanced NSCLC showed relatively high sensitivity for detecting gene mutations but low sensitivity for gene fusions and MET exon 14 skipping. This may be an alternative only when tissue assay is unavailable due to insufficient DNA and RNA. See related commentary by Jacobsen Skanderup et al., p. 1381

31 December 2022 in Lung Cancer
Verified
Journal Article
Closed access
YTYutaro Tamiya
Yutaro Tamiya
SMShingo Matsumoto
Shingo Matsumoto
YZYoshitaka Zenke
Yoshitaka Zenke
KYKiyotaka Yoh
Kiyotaka Yoh
TITakaya Ikeda
Takaya Ikeda
KGKoichi Goto
Koichi Goto

3 August 2023 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
TSTetsuya Sakai
Tetsuya Sakai
SMShingo Matsumoto
Shingo Matsumoto
YUYasuto Ueda
Yasuto Ueda
YSYuji Shibata
Yuji Shibata
TITakaya Ikeda
Takaya Ikeda
KGKoichi Goto
Koichi Goto

1 October 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
BBBatel Blechter
Batel Blechter
XWXiaoyu Wang
Xiaoyu Wang
JDJun cheng Dai
Jun cheng Dai
CKChristiana Kartsonaki
Christiana Kartsonaki
JSJianxin Shi
Jianxin Shi
HZHaoyu Zhang
Haoyu Zhang
Background: Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve lung adenocarcinoma risk prediction. Methods: PRSs were developed using genome-wide association study summary statistics from East Asian (8002 cases; 20 782 controls) and European (2058 cases; 5575 controls) populations. Single-ancestry models included a PRS with 25 single nucleotide variants (PRS-25), PRS clumping and thresholding (CT), and LDpred2; multi-ancestry models included LDpred2 plus European PRS-128, PRS-CSx, and clumping and thresholding, super learning, empirical Bayes (CT-SLEB). Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium and externally validated in the Nanjing Lung Cancer Cohort. We assessed predictive accuracy via area under the curve operating procedure (AUC), with 10-year and (ages 30-80 years) absolute risks estimates. Results: The best multi-ancestry PRS, using East Asian and European data via CT-SLEB, outperformed the best East Asian-only (LDpred2; AUC = 0.629, 95% confidence interval [CI] = 0.618 to 0.641), achieving an AUC of 0.640 (95% CI = 0.629 to 0.653) and odds ratio of 1.71 (95% CI = 1.61 to 1.82) per standard deviation increase. Nanjing Lung Cancer Cohort validation confirmed robust performance (AUC = 0.649, 95% CI = 0.623 to 0.676). The top 20% PRS group had a 3.92-fold higher lung adenocarcinoma risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year lung adenocarcinoma risk at age 50 years (0.42%) by age 41 years, 9 years earlier. Conclusions: Multi-ancestry PRS approaches enhance lung adenocarcinoma risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.

1 February 2021 in Lung Cancer
Verified
Journal Article
Closed access
YSYuji Shibata
Yuji Shibata
SMShingo Matsumoto
Shingo Matsumoto
KYKiyotaka Yoh
Kiyotaka Yoh
KGKoichi Goto
Koichi Goto